The pharmacological activation of Nrf2 has been observed to inhibit CIS-mediated nephrotoxicity, whereas the absence of Nrf2 has been reported to exacerbate CIS-induced nephrotoxicity (Li et al., 2018). This evidence concerns the gene NFE2L2 and in situ carcinoma.